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Abstract
Recent investigations have revealed that the genetic deletion of P2X7 receptors (P2rx7) results in an antidepressant
phenotype in mice. However, the link between the deficiency of P2rx7 and changes in behavior has not yet been explored.
In the present study, we studied the effect of genetic deletion of P2rx7 on neurochemical changes in the hippocampus that
might underlie the antidepressant phenotype. P2X7 receptor deficient mice (P2rx72/2) displayed decreased immobility in
the tail suspension test (TST) and an attenuated anhedonia response in the sucrose preference test (SPT) following bacterial
endotoxin (LPS) challenge. The attenuated anhedonia was reproduced through systemic treatments with P2rx7 antagonists.
The activation of P2rx7 resulted in the concentration-dependent release of [3H]glutamate in P2rx7+/+ but not P2rx72/2
mice, and the NR2B subunit mRNA and protein was upregulated in the hippocampus of P2rx72/2 mice. The brain-derived
neurotrophic factor (BDNF) expression was higher in saline but not LPS-treated P2rx72/2 mice; the P2rx7 antagonist
Brilliant blue G elevated and the P2rx7 agonist benzoylbenzoyl ATP (BzATP) reduced BDNF level. This effect was dependent
on the activation of NMDA and non-NMDA receptors but not on Group I metabotropic glutamate receptors (mGluR1,5). An
increased 5-bromo-2-deoxyuridine (BrdU) incorporation was also observed in the dentate gyrus derived from P2rx72/2
mice. Basal level of 5-HT was increased, whereas the 5HIAA/5-HT ratio was lower in the hippocampus of P2rx72/2 mice,
which accompanied the increased uptake of [3H]5-HT and an elevated number of [3H]citalopram binding sites. The LPS-
induced elevation of 5-HT level was absent in P2rx72/2 mice. In conclusion there are several potential mechanisms for the
antidepressant phenotype of P2rx72/2 mice, such as the absence of P2rx7-mediated glutamate release, elevated basal
BDNF production, enhanced neurogenesis and increased 5-HT bioavailability in the hippocampus.
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Introduction
Mood disorders, including major depressive disorder (MDD)
and bipolar disorder (BPD), are the most common psychiatric
illnesses [1,2], which are caused by complex interactions between
genes, developmental and environmental factors. Genetic research
has identified several chromosomal regions and genes involved in
the susceptibility to mood disorders, but no clear etiological
mechanism has been determined. Previous studies revealed
mutations in the gene encoding the P2X7 purinergic receptor
(P2rx7), which are associated with the development of MDD and
BPD [3,4,5,6,7,8]. Although subsequent studies have failed to
confirm this association [9,10,11], more recent data have again
reaffirmed the potential of these polymorphisms to affect the
pathology of mood disorders [12,13]. In addition, a clinical study
showed the reduced mRNA expression of the P2X7 receptor in a
set of patients suffering from depression and posttraumatic stress
disorder characterized by the increased risk of suicide [14]. P2rx7
belongs to the family of ionotropic P2X receptors that are sensitive
to ATP and other related nucleotides. These receptors are
distributed in hematopoietic cells, epithelial cells, neurons,
astrocytes, oligodendrocytes and microglia. P2rx7 plays an
important role in the processing and secretion of mature pro-
inflammatory cytokines, such as interleukin (IL)-1b, IL-18, and
tumor necrosis factor (TNF)-a, and in ATP-mediated apoptosis.
The primary role of P2rx7s in the brain is regulation of
neurotransmitter release [15,16,17]. The activation of P2rx7
results in Ca2+ influx [18], increased glutamate and GABA release
from brain slices [19,20] and nerve terminals [21,22].
Previous studies have demonstrated that the genetic deletion
and pharmacological antagonism of P2rx7 leads to an antidepres-
sant phenotype in several behavioral models [23,24,25]. We found
that P2rx72/2 mice displayed a decreased immobility response
in the forced swim (FST) and tail suspension (TST) tests, which
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can be reproduced by subacute administration of the selective
P2rx7 antagonist Brilliant Blue G (BBG). We also presented
evidence that the deletion of P2rx7 in non-hematopoietic cells
leads to the observed antidepressant phenotype. When bone
marrow chimeras were generated that lacked the P2rx7 only in
their hematopoietic compartment, no difference was found in
behavioral tests, indicating that the antidepressant phenotype
found in P2rx72/2 mice was not transferred to wild-type
recipients with the engraftment of the P2rx72/2 bone marrow
cells [25]. Consequently, the expression of P2rx7 in other cell
types, particularly neurons or astrocytes, might be responsible for
the associated changes in mood. In addition, we found that the
deficiency of P2X7 receptors leads to a widespread alteration of
the gene expression in the limbic system, including the up and
downregulation of genes crucial for synaptic transmission and
plasticity, such as glutamatergic and GABAergic receptor subunits
[25]. Consistent with these results, other studies have shown
enhanced c-Fos expression in the hippocampus of P2rx72/2
mice after repeated forced swim tests, which indicates that the
hippocampus is an important target area that mediates the effect
of P2rx7 activation on emotional behavior [24].
Despite these data, the key question how the activity of P2X7
receptor leads to alterations in animal behavior remains unknown.
It has been repeatedly shown that major depression is character-
ized by a reduction of neuronal plasticity and a 2-week
administration of antidepressant treatment is sufficient to normal-
ize this deficit and generate a neuroadaptive mechanism that
might enhance neuronal plasticity [26,27]. Neurotrophins, such as
brain-derived neurotrophic factor (BDNF), promote neuronal
survival and enhance synaptic plasticity [28]. BDNF is synthesized
as a 30–35-kDa-precursor protein, which is proteolytically cleaved
to produce a mature and functional enzyme that plays a crucial
role in the development, differentiation and survival of neuronal
populations within the central and peripheral nervous system.
Several studies have demonstrated a strong association between
the expression of BDNF and the onset of depression. Reduced
BDNF mRNA and protein expression have been detected in the
hippocampus of postmortem brains from suicide victims [29] and
serum BDNF levels are reduced in depressed patients [30].
Consistent with these findings, it has been shown that the infusion
of BDNF into the brain results in an antidepressant-like phenotype
[31]. However, the lack of BDNF is not sufficient to produce a
depressive phenotype, although it is required for the behavioral
response to antidepressants [32].
As a consequence of an alteration in the level of neurotrophic
factors, or independently from it, an aberrant regulation of adult
neurogenesis in the hippocampus has also been implicated in the
pathophysiology of MDD. Human in vivo imaging studies have
demonstrated a reduction in the volume of the hippocampus in
depressed patients [33], and this effect can be ameliorated through
antidepressant treatment [34]. Post-mortem studies also verified a
decrease in the size and/or number of neuronal cell bodies in this
brain area [35]. Studies in rodents have consistently shown that
stress is one of the most powerful stimuli that leads to a decrease in
adult neurogenesis in the hippocampus [36]. Moreover, chronic,
but not acute antidepressant treatment normalizes neurogenesis in
the adult hippocampus, and the inhibition of neurogenesis
prevents the behavioral response to antidepressants, providing a
direct link between neurogenesis and the antidepressant response
[37].
Nevertheless, other mechanisms, such as the alteration in
extracellular levels of monoamines in the brain might also be
responsible for the characteristic action of antidepressant drugs
observed in rodent models of depression [38].
In the present study, to gain insight into the cellular basis of
differential behavioral responses, we used a P2rx72/2 mouse
model to demonstrate that (1) the genetic deletion of P2rx7
induced neurochemical changes characteristic of antidepressant
treatment, such as the dysregulation of monoaminergic transmis-
sion and elevated BDNF levels in the hippocampus, and (2) the
lack of P2rx7-mediated glutamate release and inhibition of BDNF
production, resulting in an enhanced hippocampal neurogenesis is
a potential mechanism for the antidepressant phenotype.
Materials and Methods
Animals
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health and the local Animal
Care Committee of the IEM HAS approved all experimental
procedures (Permission No: 22.1/3671/003/2008). This study used
2- to 3-months old (approx. 30 g) male wild type (P2rx7+/+), and
P2rx7 knockout (P2rx72/2) mouse littermates, which were housed
under a 12 h on/12 h off light cycle with 60610% humidity in a
temperature-controlled room (2362uC). Food and water were
supplied ad libitum. Homozygous P2rx72/2 mice were bred to
C57BL/6 mice. Christopher Gabel (Pfizer Inc., Groton, CT, USA)
kindly supplied the original breeding pairs of P2rx72/2 mice
(C57BL/6J based). An overall six backcrosses on C57BL/6 were
performed for the P2rx7 knockout mouse colony used in our
experiments. Offspring of this mouse line were cross-bred with
P2rx7+/+ mice and the resulting heterozygotes were used as
breeding stock for the F1 generation offspring employed in the
behavior studies. The animals contained the DNA construct (P2X7-
F1 (59-CGGCGTGCGTTTTGACATCCT-39) and P2X7-R2 (59-
AGGGCCCTGCGGTTCTC-39)), which have been previously
shown to generate the genetic deletion of P2rx7 [39]. The animals
were genotyped using PCR analysis as described earlier [39].
Behavior Experiments
Automated Tail Suspension Test (TST). All experiments
and treatments were performed during the light phase (7.00 AM–
7.00 PM). The TST was conducted using an automated tail
suspension device (BIO-TST2, Bioseb, France) in accordance with
a previously described method [40]. The device consisted of a
single tail suspension module with three chambers, connected to a
personal computer that recorded the activity of the animals during
the test sessions. Three mice were individually suspended by the
tail onto the hooks of the device using adhesive tape (distance from
tip of tail was 1–2 cm). The measurements were automatically
recorded within 5–10 seconds after placing the last animal into the
chamber, and each measurement lasted 6 min. During the test,
the animals showed several escaping behaviors with temporary
periods of immobility. The threshold level was set at 6. To
examine endotoxin-induced depressive behavior, the animals were
subjected to bacterial lipopolysaccharide injection (LPS, serotype
055:B5, Sigma, St. Louis, MA, USA, 1 mg/kg i.p.) at 24 h before
a single 6-min test period. Brilliant blue G (BBG, 50 mg/kg i.p.) or
an equal volume of saline was injected at 30 min before the test
period. The time of immobility was expressed in sec. The P2rx7+/
+ and P2rx72/2 mice were subjected to alternation testing. In
accordance with the observations of Mayorga and Lucki (2001),
some of the animals (0–16%, depending on the experiment)
displayed tail-climbing behavior. The data of these animals were
excluded from the calculations during the post hoc analysis.
Sucrose Preference Test (SPT). The experiments were
performed using the two-bottle sucrose preference paradigm [41].
Hippocampal P2X7 Receptors and Depression
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Figure 1. Genetic deletion and pharmacological inhibition of P2rx7 results in antidepressant phenotype in mice using the TST (A, B)
and SPT (C–H) tests. A/Genetic disruption of P2rx7 expression decreases basal immobility in the TST (n = 6,10, ***P,0.001 vs. P2rx7+/+, Student t
test). The immobility time is expressed in sec. The total test period was 360 sec. B/Effect of acute BBG treatment (50 mg/kg i.p.) on LPS-induced
depressive behavior in TST. LPS was added at a dose of 1 mg/kg at 24 h before testing (n = 7–9, **P,0.01 vs. SAL, Student t test). BBG was
administered intraperitoneally at 30 min before testing; saline-treated mice (SAL) were injected with equal volume of saline. C/LPS-induced decline in
sucrose preference is attenuated in P2rx72/2 mice. Baseline sucrose intake was measured under a habituation period of 3–4 days before treatment,
and the mean volume ingested over the last 3 training sessions was used as a baseline value. The mice were treated with LPS (0.2 mg/kg i.p.) or an
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The decreased preference for sucrose vs. water in this test has been
proposed to reflect impaired sensitivity towards reward and to
model anhedonia [42]. Mice were offered a choice of 2% sucrose
solution or water during 12-hour nocturnal periods (starting at
19:00). The bottles were weighed before and after each test session
to monitor sucrose and water consumption. The relative position
of the sucrose and water bottles were swapped every night to avoid
place preferences. The baseline sucrose intake was measured
under a habituation period of 3–4 days before administering the
treatments, and the mean volume ingested over the last 3 training
sessions was used as a baseline value. The sucrose consumption
was measured for 4 consecutive nights after LPS (0.2 mg/kg i.p.)
or saline administration and expressed as g/100 g body weight or
as a percentage of the baseline (%). The LPS dosage was chosen
based on preliminary experiments, which showed that a 0.2 mg/
kg dose elicits a relatively selective anhedonia response.
[3H]Glutamate ([3H]Glu) Release Experiments
The [3H]Glu release experiments were conducted using the
method described in our previous papers [20]. Briefly, the mice
were anaesthetized under light CO2 inhalation, and subsequently
decapitated. The hippocampus was dissected from each mouse in
ice-cold Krebs solution saturated with 95% O2 and 5% CO2,
sectioned (400-mm-thick slices) using a McIlwain tissue chopper
and incubated in 1 ml of modified Krebs solution (113 mM NaCl,
4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 25.0 mM NaHCO3, and 11.5 mM glucose), pH 7.4, in
the presence of 5 mCi/ml [3H]glutamic acid ([3H]Glu, 9.861028
M, specific activity 51 Ci/mmol; Perkin Elmer) for 45 min. The
medium was bubbled with 95% O2 and 5% CO2 and maintained
at 32uC. After loading, the slices were continuously superfused
with 95% O2 and 5% CO2-saturated modified Krebs solution
(flow rate: 0.7 ml/min).
Subsequently, the perfused samples were collected over a 3-min
period and measured for tritium content. At 6 min after the start
of the collection, the slices were subjected to a 6-min perfusion of
the agonist (ATP) at various concentrations (1, 3, 6 and 10 mM)
and then changed to normal Krebs solution until the end of the
collection period. In some experiments, the P2X1 receptor
antagonist, NF449 (100 nM), or the selective P2rx7 antagonist
Brilliant blue G (100 nM) was applied to the perfusion solution at
15 min before the beginning of the ATP perfusion.
The radioactivity released from the preparations was measured
using a Packard 1900 Tricarb liquid scintillation spectrometer,
using Ultima Gold Scintillation cocktail. The release of tritium was
expressed as a percentage of the amount of radioactivity in the
tissue at the sample collection time (fractional release). The tritium
uptake in the tissue was determined as the sum of release+the
tissue content after the experiment and expressed in Bq/g. For the
evaluation of the basal tritium outflow the fractional release
measured in four consecutive 3 min samples under drug free
conditions were taken into account. The ATP-induced [3H]Glu
efflux calculated as the net release in response to the respective
stimulus by subtracting the release before the stimulation from the
values measured after stimulation. Selected samples collected
under resting conditions and during the peak of the ATP-evoked
response were subjected to further HPLC analyses.
Analysis of NR2B mRNA Expression Using Quantitative
Real-time PCR
P2rx7 wild type and knockout mice were anesthetized under
light CO2 inhalation, and subsequently decapitated. The hippo-
campus from each mouse was dissected in ice-cold Krebs solution
saturated with 95% O2 and 5% CO2, sectioned (400 mm thick
slices) using a McIlwain tissue chopper and incubated in 2 ml of
modified Krebs solution in the presence of 1 ml Hibernate
medium (Invitrogen Life Technology, Grand Island, NY, USA),
ascorbic acid (300 mM) and Na2EDTA (30 mM) for 60 min. The
medium was bubbled continuously with 95% O2 and 5% CO2
and maintained at 37uC. The hippocampal slices were collected,
frozen on dry ice and stored at 270uC until further investigation.
Each experimental group contained 3–4 mice. Total RNA samples
were isolated and purified from the cell lysates using the RNeasy
Lipid Tissue Mini Kit (Qiagen) according to the manufacturer’s
instructions. The RNA (2 ml) was reverse transcribed using the
RevertAid First Strand cDNA Synthesis Kit (Fermentas, Vilnius,
Lithuania) as described in our previous study [20,43]. Briefly, 1 mg
of total RNA reverse transcribed using 1 ml of RevertAid H Minus
M-MuLV reverse transcriptase in a mixture containing 5 ml of 5X
reaction buffer, 1 ml of random hexamer primer (10 pmol/ml), 1 ml
of RiboLockTM RNase Inhibitor (20 u/ml), and 2 ml of 10 mM
dNTP mix in a final volume of 20 ml with 0.1% diethylpyr-
ocarbonate-treated distilled water. The reverse transcription
reaction was performed at 70uC for 5 min, followed by incubation
at 25uC for 5 min, synthesis at 25uC for 10 min, and a final
incubation at 42uC for 60 min. The resulting cDNA samples were
stored at 220uC. The expression level of the target gene was
determined using the cDNA samples with quantitative real-time
PCR (Rotor-Gene 3000; Corbett Research, Sydney, Australia).
The Real-time PCR analysis was performed according to standard
protocols using a LightCycler DNA Master SYBR Green I Kit
(Roche, Indianapolis, IN, USA). The PCR conditions were
optimized for primers, templates and MgCl2. The PCR cycling
protocols was set to the following conditions: initial denaturation at
95uC for 10 min followed by 40 cycles at 94uC for 15 sec, 64uC for
30 sec, and 72uC for 10 sec. The PCR primers were based on
previous study of Xiaoping Du et al. [44]. The following primers
were used for mRNA detection: NR2B forward primer, 59 GTG
equal volume of saline (SAL), indicated by an arrow, and the sucrose intake was monitored over subsequent days. LPS substantially decreased sucrose
consumption as a sign of anhedonia (FLPS(1, 63) = 1193; P,0.0001). The sucrose consumption was expressed as a percentage of the baseline (%).
N = 9–14, *P,0.05 vs. P2rx7+/+. Two-way ANOVA, followed by Fischer LSD test. D-H/The P2X7 receptor antagonists Brilliant blue G (BBG), AZ-
10606120 (AZ), and the selective 5-HT re-uptake inhibitor citalopram (CIT) inhibit the development of LPS-induced anhedonia in P2rx7+/+ mice. D/
The antidepressant effect of a subacute, 4-day treatment with BBG (50 mg/kg i.p./day, n = 8–20, *P,0.05, vs. control). E/The effect of subacute (AZ 2
subacute) AZ-10606120 treatment on LPS-induced anhedonia. Notably, in this protocol, AZ-10606120 significantly attenuated the decline in sucrose
consumption at 24 h after LPS treatment. (FAZ (1,39) = 1179.4, P,0.00001; n = 5–9, **P,0.01, ***P,0.001 vs. control). F/The effect of acute AZ-
10606120 (AZ 2, acute) treatment on LPS-induced anhedonia. When mice were pretreated with AZ-10606120 for 30 min before LPS injection at the
doses indicated in the legend (mg/kg), sucrose consumption on the 2nd and 3rd day after LPS injection was significantly higher (n = 7–8, **P,0.01,
***P,0.001 vs. control). G and H/. Effect of 4-day subacute (CIT 15 subacute, G), and single acute treatment with citalopram (CIT 15, acute, H) on LPS-
induced anhedonia. Citalopram elicited a comparable effect to AZ-10606120 using both application protocols (n = 5–10, **P,0.01, ***P,0.001 vs.
control). The sucrose consumption in all experiments was evaluated at 0, 24, 48 and 72 h after LPS injection and expressed as a percentage of the
baseline. Two-way ANOVA, followed by Fischer LSD test was performed as statistical analyses in SPT datasets. 2–3 months old drug- and test-naive
male homozygous mice (P2rx7+/+ and P2rx72/2), weighing approximately 30 g were used in the experiments.
doi:10.1371/journal.pone.0066547.g001
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AGA GCT CCT TTG CCA AC; NR2B reverse primer, 59 GTC
AGG GTA GAG CGA CTT GC; 18S forward primer, 59-
GTAACCCGTTGAACCCCATT, and 18S reverse primer, 39-
CCATCCAATCGGTAGTAGCG.
Analysis of real-time PCR measurements. To ensure
reaction specificity and accurate quantification, a melting curve
analysis was performed after each reaction, which confirmed the
lack of primer–dimer artifacts or contamination in all cases. All
DCt values were calculated using Rotor Gene 5 software (Corbett
Research, Sydney, Australia). The expression level of the target
genes was normalized to the expression level of 18S rRNA as a
reference or housekeeping gene. The target gene and the reference
gene were measured together within the same experiment. The
efficiency calibrated model of Pfaffl was applied to compare the
expression level of target genes between the different experimental
groups [45]. Differences in the gene expression levels between the
experimental groups were considered significant when the P level
was ,0.05. Data are presented as the mean normalized expression
ratio 6 SEM.
NR2B Immunostaining
Male P2rx7+/+ or P2rx72/2 mice (62–65 days old, appr. 30 g)
from our in-house colony were used. Animals were deeply
anesthetized and perfused transcardially with 4% paraformaldehyde
in 0.1 M phosphate buffer (PB, pH 7.4). Brains were removed and
post-fixed overnight at 4uC. The block containing the whole
hippocampus was dissected out and 100 mm coronal sections were
serially sectioned with a Leica vibratome and immersed free-floating
in 0.1 M PB. After extensive washing, sections were treated with
0.2M HCl containing 0.2 mg/ml pepsin at 37uC for 15 min, then
rinsed in PB three times and washed for 3X10 min in 0.1M Tris
buffer (TBS). Nonspecific binding sites were blocked by 10% normal
horse serum (Vector Laboratories, Burlingame, CA) for 2 hours and
incubated with a mouse anti-NR2B (GluN2B/NR2B antibody (UC
Davis/NIH NeuroMab Facility) diluted 1:1000 in TBS containing
2% normal horse serum for 24 h at 4uC. After washing in TBS three
times (10 min each), anti-mouse Cy3 (Jackson ImmunoResearch
Europe Ltd. Suffolk CB8 1JX, UK) secondary antibody was applied
in 1:1000 for 2 hours at room temperature. Sections were washed in
TB, mounted on polylysine-coated slides and cover slipped with
Vectashield (Vector Laboratories). Specificity of NeuroMab
GluN2B/NR2B antibody was validated on KO tissues and it did
not cross react with glutamate receptors NR2A, NR2C or NR2D (see
information http://catalog.antibodiesinc.com/item/neuromabs/
receptors/75-097?&plpver = 10&origin = advsrch&by = prod&filter
= 0&categid = 1025&prodid = 1028).
Likely due to the HCl-pepsin treatment, careful blocking with
10% NHS and 2% NHS content in the first and second antibody
Figure 2. The effect of P2X7 receptor antagonist AZ-10606120 (AZ) and citalopram (CIT) on LPS-induced anhedonia in P2rx72/2
mice. A and C/The effect of acute AZ-10606120 (AZ 2 acute, A) and citalopram (CIT 15 acute, C) treatment on LPS-induced anhedonia. The protocols
were identical to those depicted in Fig. 1 F and H, respectively. The inhibitory effect of AZ-10606120, but not citalopram, was abolished in P2rx72/2
mice (n = 4–11, *P,0.05, **P,0.01 vs. control). B/D/Effect of subacute, 4-day treatment with AZ-10606120 (AZ, B) and citalopram (CIT, D) on LPS-
induced anhedonia. The protocol was identical to the experiments depicted in Fig. 1 E and G, respectively. Although both citalopram and AZ-
10606120 alleviated anhedonia over subsequent days in these mice, the effect of AZ-10606120, but not citalopram, was significantly attenuated
compared with the effect measured in P2rx7+/+ mice (n = 5–11, **P,0.01, ***P,0.001 vs. control, ##P,0.01 vs. subacute AZ in P2rx7+/+ mice, two-
way ANOVA, followed by Fischer LSD test).
doi:10.1371/journal.pone.0066547.g002
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Figure 3. The effect of the genetic deletion of P2rx7 on ATP-evoked tritiated (A, C) and endogenous (B) glutamate efflux (D) mRNA
expression and (E–I) immunofluorescence staining of the NR2B subunit of the NMDA receptors in acute hippocampal slices. A/
10 mM ATP was used to induce [3H]Glu release from hippocampal slices of P2rx7+/+ and P2rx72/2 mice. After a 60-min preperfusion, the basal
extracellular [3H]Glu efflux was lower in P2rx72/2 mice. 6-min perfusion of ATP (10 mM) resulted in a transient increase in the efflux of [3H]Glu in
P2rx7+/+ mice, which peaked at 6 min after ATP administration and gradually decreased to baseline levels after 12 min. The ATP-evoked [3H]Glu
efflux is substantially decreased in the hippocampus of P2rx72/2mice, and the residual efflux is abolished by the selective P2X1 receptor antagonist
NF449 (100 nM), which was applied at 15 min before ATP perfusion. [3H]Glu release is expressed as a percentage of the amount of radioactivity in the
tissue at the sample collection time (fractional release). For the evaluation of the basal tritium outflow, the tritium content of the first four consecutive
3-min samples were taken into account. The curves represent the mean 6 SEM of 8–12 identical experiments. B/HPLC analysis. Samples indicated in
Hippocampal P2X7 Receptors and Depression
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solutions could not prevent some background staining in blood
vessels. However, the similar intensity of this staining in P2rx7+/+
and P2rx72/2 hippocampal sections can illustrate the same
image acquisition and editing parameters.
Confocal images were acquired at the same depth of the
sections at same acquisition parameters with a Nikon A1R
confocal system on an inverted Nikon Ti-E microscope (objective
20X DIC N1, numerical aperture 0.45 for large images and Plan
Apo VC 606Oil DIC N260X, numerical aperture 1.4 for details)
equipped with NIS-Elements C software. Images were edited,
brightness as well as contrast were adjusted using Adobe
Photoshop CS3 (San Jose, CA, USA). The average intensity of
NR2B immunostaining was quantified with NIH ImageJ program
(U.S. National Institutes of Health, Bethesda, MD).
BDNF Protein Assay
Ex vivo study. The P2rx7 wild type and knockout mice
received an intraperitoneal injection of sterile saline (0.9% NaCl)
or LPS from E. Coli (Sigma, 055:B5; 1 mg/kg; 0.1 ml/mouse) and
decapitated at 24 h later. The hippocampus was collected, frozen
on dry ice and stored at 270uC until further investigation. Each
experimental group contained 4–6 mice.
In vitro study. The P2rx7 wild type and knockout mice were
anesthetized under light CO2 inhalation and decapitated. The
hippocampus was dissected in ice-cold Krebs solution saturated
with 95% O2 and 5% CO2, sectioned (400 mm thick slices) using a
McIlwain tissue chopper and incubated in 2 ml of modified Krebs
solution in the presence of 1 ml Hibernate medium [28], ascorbic
acid (300 mM) and Na2EDTA (30 mM) for 60 min. The medium
was bubbled continuously with 95% O2 and 5% CO2 and
maintained at 37uC. The P2rx7 agonist, BzATP, was added to the
incubation solution for 30 min, whereas BBG was applied 15 min
before BzATP application. RO-256981, 6-cyano-7-nitroquinoxa-
line-2,3-dione (CNQX) and 3-Chloro-4-fluoro-N-[4[[2(phenylcar-
bonyl)hydrazino]carbonyl]benzyl] benzenesulfonamide (TCN-
201) were applied for 15 min, while MCPG was administered
for 30 min. The group I metabotropic glutamate receptor agonist,
dihydroxyphenylglycine (DHPG), was administered for 10 min.
The DHPG, MCPG, and RO-256981 dosages were chosen based
on previous studies [46,47,48]. In the experiments with BzATP,
Mg2+ was omitted from the incubation solution. The hippocampal
slices were collected, frozen on dry ice and stored at 270uC until
further investigation. Each experimental group contained 3–4
mice.
BDNF protein measurement. At the time of analysis, the
samples were removed from the freezer and weighed. The BDNF
extraction procedure was performed in accordance with the
methods of a previous study [49]. For the BDNF assays, 2 ml lysis
buffer (100 mM PIPES, pH 7, 500 mM NaCl, 0.2% Triton X-
100, 0.1% NaN3, 2% BSA, 2 mM EDTA, 200 mM PMSF, 10 mg/
mL aprotinin, 1 mg/mL leupeptin, and 0.5 mM sodium vanadate)
was added to each sample, and the hippocampus was sonicated at
power level 2 using pulses at 1 sec intervals for 10–15 sec.
Subsequently, the samples were centrifuged at 16,000 6 g for
30 min at 4uC. 100 ml aliquots of the resulting supernatants were
removed and diluted with 400 ml of DPBS buffer (137 mM NaCl,
2.68 mM KCl, 1.47 mM KH2PO4, 8.1 mM Na2HPO4 (pH 7.35),
0.9 mM CaCl2?H2O, and 0.5 mM MgCl2?H2O). The superna-
tants were collected and stored at 270?C until further analysis.
For the total free BDNF measurement, the samples were acid
treated with 1 ml of 1 N HCl for each 50 ml of diluted samples to
decrease the pH to 2.5, followed by incubation at room
temperature for 15 min. The samples were neutralized with 1 ml
of 1 N NaOH for each 50 ml of diluted samples. The levels of
BDNF (both precursor and mature forms) expression were
evaluated using an enzyme-linked immunosorbent assay (ELISA)
kit and a BDNF Emax ImmunoAssay System (Promega Corpo-
ration, Madison, WI, USA), which is specific for mouse BDNF
protein, according to the manufacturer’s instructions. The BDNF
levels were calculated by plotting the optical density (OD) of each
sample against the standard curve. A seven-point standard curve
using two-fold serial dilutions in Reagent Diluent (according the
manufacturer’s instructions) and a high standard of 500 pg/ml
were used for the determination of BDNF levels. The assay
detection limits were ,15 pg/ml. Absorbance was measured at
450 nm using a Perkin-Elmer Victor 3V 1420 Multilabel Counter.
5-Bromo-2-deoxyuridine (BrdU) Incorporation
Experiment
BrdU staining procedure. Male P2rx7+/+ and P2rx72/2
mice were used. The animals received intraperitoneal injections of
150 ml (3650 mg/kg body weight) BrdU Labeling Reagent
(Invitrogen) for 3–5 consecutive days. The animals were anesthe-
tized and sacrificed on the day after the last injection of BrdU. The
animals were perfused transcardially with 4% paraformaldehyde
in 0.1 M phosphate buffer (PB, pH 7.4). The brains were removed
and post-fixed overnight at 4uC. The entire hippocampus was
dissected, and 40 mm coronal sections were serially sectioned using
a Leica vibratome and immersed free-floating in 0.1 M PB. A one-
in-six series of sections from every animal was used for the cell
counts. The sections were washed (365 min) in 0.1 M PBS
(pH 7.4). Peroxidase labeling was used to assess BrdU incorpora-
(A) as S1 and S2 were analyzed. ATP perfusion (10 mM) significantly increases the endogenous Glu level in the effluent. Results are expressed as
pmol/3 min. N= 8, ***P,0.001. C/Concentration-response relationship of ATP-evoked [3H]Glu efflux in P2rx7+/+ and P2rx72/2 mice. Experiments
were performed according to the protocol shown in (A), using different concentrations of ATP, as indicated in the abscissa. The net ATP-induced
release was calculated and expressed as the fractional release (%). The curves represent the mean 6 S.E.M. of 4–12 identical experiments. D/Changes
in the mRNA expression levels of the NMDA-NR2B receptor in hippocampus obtained from P2rx7+/+ and P2rx72/2 mice. Immediately after the 60-
min incubation, the brain slices were removed and total RNA was extracted from the hippocampus and reverse transcribed to cDNA. Quantitative
SYBR Green real-time PCR was performed using specific primers, as described in Methods, and cDNA as a template. The experiments were repeated
two times with similar results. The expression level of the NR2B receptor was normalized to that of the distinct housekeeping gene, 18S rRNA. The
data are displayed as the mean 6 SEM. Asterisk indicates significant difference from the P2rx7+/+ mice (*P,0.05, Student’s t-test). E-I/
Immunofluorescence staining for NR2B on hippocampal sections of P2rx7+/+ and P2rx72/2 mice. Besides the typical dotted staining most likely
presenting NR2B - immunolabelled terminals (arrows, F, H) some staining is observable around cell bodies especially in the pyramidal cell layer (three
arrowheads G). The whole staining is more intense in the hippocampal section of P2rx72/2mouse (G, I). The most intense staining is observed in the
CA3 regions (CA3 on E, G and F, H), while stratum oriens (or) shows the least immunoreactivity either in P2rx7+/+ and P2rx72/2 sample. Contrary to
P2rx7+/+ staining (E), intense immunofluorescence illustrates hilus region on P2rx72/2 (G) sample. Images acquired at higher magnification (F,H)
also show blood vessels (arrowheads), stained at the same level in both sections (background staining). bars: 50 mm in F, H, 500 mm in E, G. I.
Immunofluorescence staining intensity for NR2B in P2rx7+/+ and P2rx72/2 mice. Average intensity was quantified with NIH ImageJ program (U.S.
National Institutes of Health, Bethesda, MD) and is expressed in arbitrary units. Asterisk indicates significant difference from the wild type mice
(*P,0.05, Student’s t-test, n = 3).
doi:10.1371/journal.pone.0066547.g003
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Figure 4. P2rx7 participates in the regulation of the basal BDNF expression in the mouse hippocampus. A/BDNF protein expression in
the hippocampus of P2rx7+/+ and P2rx72/2 mice after saline (Sal) and LPS (1 mg/kg i.p.) treatment. Intraperitoneal injection of LPS significantly
decreased the level of BDNF expression in the hippocampus of P2rx7+/+mice at 24 h after treatment compared with saline treatment (Sal). The BDNF
protein level was significantly higher in the hippocampus of saline treated P2rx72/2 mice. The animals were sacrificed at 24 h after the injection of
LPS/saline. The data are given as the mean level of neurotrophin 6 SEM. Asterisks indicate significant differences between the saline and LPS-treated
groups and between the WT and P2rx72/2 groups (n = 4–6, *P,0.05, *** P,0.001). B, C Effect of the P2X7 receptor antagonist BBG (B) and the P2X
agonist BzATP (C) on the basal level of BDNF in the hippocampus of P2rx7+/+ and P2rx72/2 mice. The P2rx7 antagonist Brilliant Blue G (BBG,
100 nM) was applied 15 min before the start of BzATP incubation, and BzATP (100 mM) was added for 30 min. Notably, in the experiments with
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tion, therefore we applied 1% H2O2 for 30 min at RT to destroy
endogenous peroxidase activity. After subsequent washing in PBS,
the sections were transferred to 2 N HCl for 30 min at 37uC for
DNA denaturation, rinsed in borate buffer (twice 10 min each),
followed by a final rinse in PBS. The sections were incubated with
a mouse anti-BrdU (Sigma, B8434) antibody diluted 1:2000 in
PBS containing 3% normal horse serum and 1% Triton X-100 for
24 h at 4uC. The ImmPRESS Universal Antibody Kit was used
according to the manufacturer’s instructions (Vector Laboratories,
Burlingame, CA) and diaminobenzidine with Ni intensification
(DAB-Ni) was used as the chromogen. The sections were dried on
glass slides, cleared with xylene and coverslipped with Depex
(Sigma, Aldrich Co, St. Louis, MO, USA).
BrdU-positive cell counting. To compare the number of
BrdU-positive cells in the rostral hippocampus of P2rx7+/+ and
P2rx72/2 mice, a one-in-six series of coronal sections (200 mm
apart) were drawn using a camera lucida with 206 objective.
BrdU-positive (BrdU +) cells were counted in the granule cell
layer, including the subgranular zone (defined as the 50 mm zone
adjacent to the inner edge of the granule cell layer). The same
areas and number of sections were investigated in each mouse, and
we considered a cell as BrdU positive if the nucleus was completely
filled with DAB-Ni endproduct. The result was expressed as the
average number of BrdU-positive cells in a hippocampal section.
Bright field microscopy was performed using a Zeiss microscope
equipped with 206 objective lens for bright field imaging. The
unpaired Student’s t-test with Welch’s correction was applied as a
statistical test.
HPLC Determination of Endogenous Noradrenaline (NA),
5-hydroxytryptamine (5-HT) and Glutamate (Glu)
The animals were sacrificed by decapitation, and the hippo-
campus was dissected and frozen in liquid nitrogen. The frozen
tissue was weighed and homogenized in ice-cold 0.1 M perchloric
acid containing 10 mM theophylline as internal standard and
0.5 mM sodium metabisulfite. The suspension was centrifuged at
3006g for 10 min at 4uC. The perchloric anion was precipitated
using 1 M KOH and separated through centrifugation. The
protein content of the pellet fraction was determined according to
the method of Lowry [50]. The supernatant was stored at 220uC
until further analysis. The biogenic amines were measured using
two-dimensional reversed-phase and ion-pair reversed-phase
chromatography as previously described [51] using a Gilson
liquid chromatographic system (Gilson Medical Electronics Inc.,
Middletown, WI, USA) equipped with an Applied Biosystems
785/A UV and BAS CC-4 amperometric detector in a cascade
line. The separations were performed on a 3 mm Discovery C18
HS (15064.0 mm) analytical column, and the biogenic amines
were measured at a 0.73-V potential electrochemical detection.
The retention order of monoamines was NA 14.7 min, 3,4-
dihydroxyphenylacetic acid (DOPAC) 16.8 min, 5-hydroxy in-
doleacetic acid (5-HIAA) 19.3 min, dopamine (DA) 25.5 min,
homovanillic acid (HVA) 26.8 min, 3-methoxytyramine (3-MT)
31.2 min and 5-HT 39.3 min.
The separation of pre-column dansylated amino acids was
performed using a gradient elution-working mode at ambient
temperature. The mobile phase A consisted of 5/95 (v/v) 78/22
acetonitrile/methanol in 15 mM ammonium formate buffer, and
the mobile phase B was composed of 90/10 (v/v 78/22)
BzATP (C), Mg2+ was omitted from the incubation solution (see Methods). The data are given as the mean level of neurotrophin 6 SEM. Asterisks
indicate significant differences calculated by one-way ANOVA followed by Dunnett’s test (multiple comparisons) and Student’s t-test (pairwise
comparisons) (*P,0.05, **P,0.01,***P,0.001). D/Effect of glutamate receptor antagonists and agonist on the basal and BzATP-induced decrease in
BDNF expression in hippocampal slices of P2rx7+/+ mice. The inhibitory effect of BzATP (100 mM) could be counteracted using CNQX (10 mM), the
non-NMDA-type glutamate receptor antagonist, TCN-201 (10 mM), the NMDA-NR1/NR2A glutamate receptor antagonist and RO-256981 (3 mM) the
NMDA-NR2B glutamate receptor antagonist but not using MCPG (200 mM), the group I mGluR antagonist. CNQX, TCN-201 and RO-256981 was added
for 15 min, MCPG was applied for 30 min, and the group I mGluR agonist, DHPG (100 mM), was administered for 10 min. Data are given as the mean
level of neurotrophin6 SEM with and without (first columns) the indicated antagonists in the presence (BzATP) or absence (CTRL) of BzATP. Asterisks
indicate significant differences calculated using one-way ANOVA followed by Dunnett’s test and Student’s t-test (ns P.0.05, **P,0.01), as
appropriate, indicated by the horizontal bars.
doi:10.1371/journal.pone.0066547.g004
Figure 5. Summary of BrdU staining in P2rx7+/+ (A) and P2rx72/2 (B) mice. A, B/Representative sections show rostral hippocampal DG
areas in 161 sections of male wild type and P2rx7 knock out mice. Dark dots (arrowheads) represent the BrdU-positive cells (ImmPress-DAB-Ni
staining). Camera lucida drawings of the same sections where the newly formed BrdU-labeled cells are indicated. The microscopic picture and
drawing were taken at the same magnification (20X), and the bar indicates 100 mm. Histogram showing the average number of BrdU-positive cells in
a rostral hippocampal DG area in the granule cell layer and in the 50-mm zone adjacent to its inner edge. C/We observed a significant difference (n = 5,
p = 0.046) in the average number of labeled cells in the sections of P2rx7+/+ and P2rx72/2 mice.
doi:10.1371/journal.pone.0066547.g005
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acetonitrile/methanol in ammonium formate buffer, pH 3.7. The
mobile phase B increased linearly (at 0.11 min to 50% 17 min to
72% and 26 min to 100%, followed by a final run to 54 min), the
flow rate was 0.7 ml/min. The analytical and the trap column
were equilibrated for 10 min, and enrichment and clean-up
procedures were performed. The dansylated derivatives were
detected using an absorbance detector (Agilent 1100) at a 319 nm
wavelength. The retention time of the dansylated Glu was
11.4 min. Pre-column derivatization was performed by mixing
50 ml of dansyl chloride prepared by dissolving 5 mg 5-
(dimethylamino)naphthalene-1-sulfonyl chloride in acetonitrile
daily and adding 50 ml of 2 M sodium carbonate, which contained
norvaline (20 mM) as an internal standard in 25 ml of sample. After
a 10-min reaction time at 60uC, the mixture was acidified using
25 ml of 6 M formic acid and injected onto the ‘‘trap-column’’.
The concentrations of the separated compounds were calculat-
ed using a two-point calibration curve internal standard method:
(Ai * f * B)/(C * Di * E) (Ai: Area of component; B: Sample
volume; C: Injection volume; Di: Response factor of 1 pmol of
standard; E: Protein content of sample; f: factor of Internal
Standard (IS area in calibration/IS area in actual)). The data were
expressed as pmol/mg protein (NA, 5-HT) or pmol per 3 min
sample (Glu).
[3H]NA and [3H]5-HT Release Experiments
[3H]NA and [3H]5-HT release was studied as described
previously with small modifications [43,52]. Briefly, mice were
anaesthetized under light CO2 inhalation and decapitated. The
hippocampi were dissected in ice-cold Krebs’ solution saturated
with 95% O2 and 5% CO2, and 400 mm thick slices were
prepared. Slices were incubated for 45 min in 1 ml of modified
Krebs’ solution saturated at 95% O2 and 5% CO2, and containing
[3H]5-HT or [3H]NA (10 and 5 mCi/ml, specific activity 24 and
30 Ci/mmol, respectively, Amersham, Little Chalfont, UK),
Figure 6. Genetic deletion of P2rx7 leads to the alteration of NA and 5-HT levels (A, B), elevation of 3H-Citalopram binding sites and
5-HT uptake (C) in the mouse hippocampus. A, B/NA and 5-HT levels were analyzed using HPLC in the hippocampus of naive and LPS (1 mg/
kg)-treated P2rx7+/+ and P2rx72/2 mice. A/5-HT levels are significantly elevated in the hippocampus of untreated P2rx72/2 mice. LPS treatment
increases 5-HT levels in the hippocampus of P2rx7+/+ mice. This elevation is absent in P2rx72/2 mice. B/NA levels are significantly decreased in the
hippocampus of untreated, but not in LPS-treated P2rx72/2mice. NA and 5-HT levels are expressed as pmol/mg protein. Data are given as the mean
6 SEM of 13–22 experiments. Asterisks denote significant differences related to genotype or LPS treatment (*P,0.05, **P,0.01, ***P,0.001). C/The
number (Bmax) of [
3H]Citalopram recognition sites was increased in the membrane preparation, and the synaptosomal 5-HT uptake was enhanced in
the hippocampus of P2rx72/2mice (black bars) compared with their P2rx7+/+ littermates (clear bars). Citalopram binding was expressed as fmol/mg
protein, and the 5-HT uptake was expressed as fmol/mg protein/10 minutes. Experiments in P2rx7+/+ and P2rx72/2 mice were performed in the
same assay. Binding parameters were calculated using Prism3 software. For experimental procedures, see Methods section. Data are given as the
mean 6 SEM of four independent experiments, * P,0.05.
doi:10.1371/journal.pone.0066547.g006
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ascorbic acid (300 mM) and Na2EDTA (30 mM). Thereafter, slices
were transferred to tissue chambers, and preperfused for 1 hour
(flow rate: 0.65 ml/min) with modified Krebs’ solution. In [3H]5-
HT release experiments, the medium also contained the serotonin
reuptake inhibitor citalopram (300 nM). After washing, 3 min
perfusate samples were collected and assayed for [3H]5-HT/
[3H]NA. At 6 and 36 min, two identical periods of electrical field
stimulations (S1, S2; 25 V, 1 msec, 2 Hz, 240 shocks) were
delivered by a Grass S88 stimulator (Grass Instruments, Quincy,
MA, USA). The temperature was maintained at 37uC throughout
the experiment. The radioactivity released from the preparations
was measured as described above ([3H]Glu release experiments)
and tritium efflux was expressed in becquerel per gram (Bq/g).
Electrical stimulation-induced [3H]5-HT/[3H]NA efflux (S1, S2)
was expressed as the area-under-the-curve of the net release.
Previous HPLC analyses showed that tritium efflux is a good
marker of [3H]5-HT/[3H]NA release under similar experimental
conditions [43,52].
3H-Citalopram, 3H-Nisoxetine and 3H-Dihydroalprenolol
Binding Experiments
Male mice (80–85 days old) were decapitated, and the
hippocampus was dissected, weighted, and frozen overnight at
270uC. The next day, the tissue from four animals was pooled,
homogenized in incubation buffer using an Ultra-Turrax and
centrifuged at 40 0006g for 15 minutes. The pellet was washed by
repeated resuspension in buffer, followed by centrifugation. The
final pellet was resuspended in 30 volumes (w/v) of buffer and used
immediately for the binding experiments. 3H-Citalopram (sp.act.
70 Ci/mmol) and 3H-Nisoxetine (sp.act. 85.5 Ci/mmol) binding
was performed in a final volume of 250 ml of 50 mM Tris-HCl
buffer, pH 7.4, containing 120 mM NaCl and 5 mM KCl. 3H-
DHA (sp.act. 88 Ci/mmol) binding was measured in 50 mM Tris-
HCl buffer, pH 7.4. Eight ligand concentrations (0.1–4 nM) were
used in three parallels. The incubation time was 1 hour at 25uC for
citalopram, 2.5 hrs at 4uC for nisoxetine and 30 minutes at 25uC
for dihydroalprenolol. The non-specific binding was determined in
the presence of 1 mM paroxetine (citalopram), 10 mM desmethyl-
imipramine (nisoxetine) and 1 mM (-) alprenolol (DHA). The
membranes of P2rx7+/+ and P2rx72/2 mice were assayed in
parallel. The binding was terminated using vacuum filtration on
GF/B filters soaked in 0.05% polyethylenimine. The Kd and the
number of binding sites (Bmax) were calculated using Prism3
software. The protein concentration (approx. 0.5 mg/ml) was
measured according to Lowry method [50] using CuEDTA.
Measurement of 3H-5HT Uptake in Synaptosomal (P2)
Preparation of Mouse Hippocampus
The hippocampus of each mouse (80–85 days old) was
homogenized in 0.32 M sucrose solution (1:10 g/ml) using a
Teflon pestle homogenizer and centrifuged at 1,0006g for 10
minutes. The supernatant was centrifuged at 12,0006g for 20
minutes. The pellet containing synaptosomes was suspended in
0.32 M sucrose (1:30 g/ml). Aliquots of the synaptosomal
suspension were preincubated for 5 min at 376C, in a final
volume of 1 ml oxygenated (95% O2+5% CO2) Krebs solution
containing 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM
KH2PO4, 1.2 mM MgSO4, 10 mM D-glucose, 25 mM NaHCO3,
0.3 mM ascorbic acid and 0.01 mM pargyline (pH 7.4). After
preincubation, 3H-5HT (10 nM) was added, and the incubation
was continued for 10 min. The uptake was terminated by addition
of cold physiological saline, and by vacuum filtration of the
samples through GF/B filters. The non-specific uptake was
determined by incubation of the samples at 0uC. The protein
content was measured using Lowry method [50]. The uptake in
synaptosomal preparations from P2rx7+/+ and P2rx72/2 mice
was measured in the same assay.
Materials
39-O-(4-benzoyl-benzoyl)adenosine 59-triphosphate, (BzATP,
Tocris), bacterial lipopolysaccharide (LPS, serotype 055:B5,
Sigma), Brilliant blue G, (BBG, Tocris), 6-cyano-7-nitroquinoxa-
line-2,3-dione (CNQX, Tocris), 4,49,499,4999-[Carbonylbis(imino-
Table 1. Resting and electrical stimulation evoked [3H]5-HT and [3H]NA efflux in the hippocampus of P2rx7+/+ and P2rx72/2
mice, respectively.
[3H]5-HT [3H]NA
P2rx7+/+ P2rx72/2 P2rx7+/+ P2rx72/2
Resting efflux (Bq/gx103) 3.5760.29 (12) 3.2860.18 (12) 3.4060.88 (12) 2.4160.21 (12)
Evoked efflux (S1, Bq/gx103) 4.1260.7 (12) 3.6860.66 (12) 14.6162.29 (12) 6.7362.08* (12)
Tissue slices were loaded with [3H]5-HT or [3H]NA and then superfused with Krebs’ solution. After 60 min preperfusion, slices were stimulated electrically with the
following parameters: 25 V, 1 msec, 2 Hz, 240 shocks. The release of radioactivity was expressed in Bq/g. For the calculation of the resting [3H]5-HT/[3H]NA efflux, the
tritium content of the sample collected immediately before the first electrical stimulation period was taken into account. Electrical stimulation-induced [3H]5-HT/[3H]NA
efflux (S1) was expressed by calculating the net release in response to electrical stimulation by the area-under-the-curve method. The number of experiments are in
parentheses. *P,0.05, significantly different from P2rx7+/+ mice, calculated by the Student’s t-test.
doi:10.1371/journal.pone.0066547.t001
Table 2. Kinetic characteristics of 3H-Citalopram, 3H-
Nisoxetine and 3H-Dihydro-alprenolol binding in the
hippocampus of P2rx7+/+ and P2rx72/2 mice.
P2rx7+/+ P2rx72/2
Kd
(nM)
Bmax
(fmol/mg
protein)
Kd
(nM)
Bmax
(fmol/mg
protein)
3H-citalopram
(n = 4)
1.260.1 555635 1.460.1 690642*
3H-nisoxetine
(n = 6)
0.760.05 126.864.9 0.760.1 131.467.5
3H-dihydroalprenolol
(n = 3)
0.560.02 44.861.1 0.460.02 45.760.7
The number (Bmax) of
3H-Citalopram recognition sites is significantly increased
in the hippocampus of P2rx72/2 mice compared with P2rx7+/+ mice
(*P,0.05). For details of the procedures, see Methods. N = number of
independent experiments.
doi:10.1371/journal.pone.0066547.t002
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5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic
acid, octasodium salt (NF449, Tocris), 3,5-dihydroxyphenylglycine,
(DHPG, Tocris), a-Methyl-4-carboxyphenylglycine (MCPG, To-
cris), (aR,bS)-a-(4-Hydroxyphenyl)-b-methyl-4-(phenylmethyl)-1-pi-
peridinepropanol maleate (RO-256981, Tocris), 3-Chloro-4-fluoro-
N-[4[[2(phenylcarbonyl)hydrazino]carbonyl]benzyl] benzenesulfo-
namide (TCN-201, Tocris), [3H]glutamic acid ([3H]Glu), [3H]-
5HT, [3H]-NA, [3H]-Citalopram, [3H]-Nisoxetine, [3H]-Dihy-
droalprenolol (Perkin Elmer), sucrose (Sigma).
Statistics
All data were presented as the mean 6 SEM of n determina-
tions. The statistical analyses were performed using one-way
ANOVA followed by Dunnett’s post-hoc test (multiple compar-
isons) and the unpaired Student’s t-test (pair-wise comparisons), as
appropriate. The SPT datasets and resting [3H]Glu outflow were
analyzed by two-way ANOVA followed by Fischer LSD test. The
level of significance was set at P,0.05.
Results
Behavior Experiments
Using automated recording, the basal time of immobility was
189.769.7 sec (n = 6) during the 6-min tail suspension test (TST)
in P2rx7+/+ mice. This value significantly decreased in the
P2rx72/2 mice (Fig. 1A). The time of immobility was also
examined 24 h after LPS (1 mg/kg i.p.) injections in P2rx7+/+
mice, i.e., when acute symptoms of the LPS induced sickness
behavior is restored [41]. The basal time of immobility was
significantly increased in response to systemic LPS challenge, i.e.,
the mice displayed depressive-like behavior (Fig. 1B). The LPS-
induced depressive behavior was significantly attenuated in mice
pretreated with the selective P2rx7 antagonist, Brilliant blue G
(50 mg/kg i.p.) (Fig. 1B).
In addition to TST, which examines active coping with
behavioral stress, we also employed the sucrose preference test
(SPT) to assess anhedonia, which is another core symptom of
depression [53]. The basal sucrose consumption in P2rx7+/+ mice
was 25.0460.76 g/100 g (n = 74), and their water and food
consumption was 7.160.32 g/100 g and 10.5760.27 g/100 g
(n = 74), respectively. In these experiments, a lower (200 mg/kg
i.p.) LPS dose was applied, which elicited a relatively selective
anhedonia response in our preliminary experiments. Indeed, the
LPS (200 mg/kg i.p.) injection elicited a significant decrease in
sucrose, but not water consumption at 24 h later in P2rx7+/+
mice (Fig. 1C), indicating the development of anhedonia; the
sucrose consumption was restored in the subsequent days and
approached the baseline value at 3 days after the treatment
(Fig. 1C). The basal sucrose consumption in P2rx72/2 mice was
25.8960.94 g/100 g (n = 60), which was not significantly different
from that observed in P2rx7+/+ mice. The water consumption
was 6.5860.29 g/100 g (n = 60, P.0.05), and the food consump-
tion was 9.8260.25 g/100 g (n = 60, P.0.05), which was also
similar to those observed in P2rx7+/+ mice. The LPS treatment
also decreased sucrose consumption in P2rx72/2 mice; however,
the decrease was less pronounced (Fig. 1C).
Next, we examined the effect of two P2rx7 antagonists, BBG
and AZ-10606120, in comparison with the selective 5-HT re-
uptake inhibitor antidepressant drug, citalopram, which was used
as a reference compound. A subacute, 4-day application of BBG
(50 mg/kg i.p.) did not change the sucrose consumption in
P2rx7+/+ mice at one day after LPS injection, but this treatment
significantly increased sucrose consumption over subsequent days
(Fig. 1D), i.e., the mice exhibited an antidepressant phenotype.
The administration of AZ-10606120 (2 mg/kg i.p.), another P2rx7
antagonist, elicited a more robust antidepressant response, which
not only resulted in the restoration of the decline in sucrose
consumption, but the amount of sucrose consumed on the day
after LPS injection was significantly higher after the subacute
treatment (Fig. 1E). Treatment with AZ-10606120 (2 mg/kg i.p.)
also promoted the restoration of the anhedonia upon acute
injection, and on the 3rd day after LPS injection, the mice
consumed significantly higher amount of sucrose (Fig. 1F). Similar
responses were observed after 4-day subacute (Fig. 1G) and acute
(Fig. 1H) treatments with citalopram. None of the treatments
significantly altered water consumption under basal conditions or
after LPS treatments (data not shown).
The inhibitory effect of acute AZ-10606120 (2 mg/kg i.p.)
treatment on LPS-induced anhedonia was completely absent in
P2rx72/2 mice (Fig. 2A). The effect of subacute AZ-10606120
(2 mg/kg i.p.) treatment on LPS-induced anhedonia was also
significantly attenuated in the deficiency of P2rx7 (Fig. 2B). By
contrast, the effect of acute (Fig. 2C) and subacute (Fig. 2D)
citalopram treatment was largely preserved in P2rx72/2 mice.
[3H]Glutamate Release in Acute Hippocampal Slices
After loading the hippocampal slices with [3H]Glu, the uptake
of radioactivity was 380668 kBq/g (n = 12) in the hippocampal
slices of P2rx7+/+ mice and 390646 kBq/g (n = 8, P.0.05) in the
P2rx72/2 mice; these results were not significantly different. The
basal efflux of [3H]Glu, when measured in a single sample was
3.3360.08% (n = 12) and 3.1460.05% (n = 8, P.0.05) in
P2rx7+/+ and P2rx72/2 mice, respectively. However, when
four consecutive samples under drug free conditions were taken
into account, two-way ANOVA indicated a significant genotype
effect (F(1,27), P,0.001, Fig. 3A), which is indicative for a lowered
extracellular Glu level in the hippocampus of P2rx7 deficient mice.
A 6-min perfusion with the P2rx7 agonist, ATP (1–10 mM),
elicited a rapid and concentration-dependent increase in the efflux
of [3H]Glu, which was reversible upon washout (Fig. 3A, C). The
net release of tritium evoked in response to 10 mM ATP was
3.3460.57% (n = 12, Fig. 3C). The endogenous glutamate content
of the samples collected during resting condition and at the peak of
ATP-evoked response was also determined using HPLC analysis
(Fig. 3B), and a remarkable elevation in the level of glutamate was
observed in response to ATP application.
When the hippocampal slices derived from P2rx72/2 mice
were challenged with ATP, using an identical protocol, only a
slight elevation in the efflux of [3H]Glu was detected at ATP
concentrations of 10 mM (0.2560.43%, n = 8, P,0.001, Fig. 3A)
and lower (Fig. 3C). The residual elevation of [3H]Glu efflux in the
presence of ATP (10 mM) was sensitive to inhibition through the
P2X1 receptor selective antagonist NF449 (100 nM) (Fig. 3A). In
contrast, the selective P2rx7 antagonist Brilliant blue G (100 nM)
did not affect the residual [3H]Glu efflux in P2rx72/2 mice
(0.5660.25%, n = 9, P.0.05).
Analysis of NR2B mRNA Expression Using Quantitative
Real-time PCR and NR2B Protein Immunofluorescence
Hippocampal slices from P2rx7+/+ and P2rx72/2 mice were
incubated in vitro with Hibernate medium containing Krebs
solution for 60 min. Changes in the level of mRNA transcripts
of the NR2B glutamate receptor subunits were measured using
real-time RT-PCR. The gene expression level was normalized to
the expression of the 18S rRNA reference gene. The results
revealed that the NR2B receptor mRNA level was upregulated to
1.8960.0015 of the corresponding wild type values, (established as
1) normalized to 18S rRNA (Fig. 3D, n = 4, P,0.05).
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The NR2B protein immunostaining was not evenly distributed
on the hippocampal sections of P2rx7+/+ and P2rx72/2 mice
(Fig. 3E, F, G, H). In general, the staining was more intense on
sections of P2rx72/2 origin (Fig. 3I). Whereas high immunore-
activity for N2RB was found in hilus region in hippocampal
sections of P2rx72/2 mice and weak in the P2rx7+/+ mice, the
staining pattern was otherwise rather similar in both cases (Fig. 3
E, G). The most intensive punctate immunostainng was observed
in the CA3 region, while stratum oriens was weakly stained.
BDNF Protein Assay
In subsequent experiments, P2rx7+/+ and P2rx72/2 mice
were challenged with an i.p. injection of 1 mg/kg LPS, and the
BDNF expression was evaluated in the hippocampus at 24 hours
after the treatment. The basal level of BDNF in the hippocampus
of P2rx7+/+ mice at 24 h after saline administration was
52.0461.31 pg/ml (Fig. 4A, n = 6). The systemic LPS adminis-
tration caused a remarkable decrease in BDNF levels (Fig. 4A,
39.4660.85 pg/ml, n = 8, P,0.001; 24.11% decrease). The basal
BDNF level in the hippocampus of P2rx72/2 mice was
63.861.15 pg/ml (n = 8), which was significantly higher than in
P2rx7+/+ mice (Fig. 4A, P,0.001). However, the LPS treatment
also attenuated the BDNF protein expression in the hippocampus
of P2rx72/2 mice (P2rx72/2: 51.9765.87 pg/ml, 17.46%
decrease; n = 8, P,0.05, Fig. 4A).
To explore the regulatory role of P2X7 receptors in the local
modulation of BDNF production, the neurotrophin levels in
hippocampal slices in P2rx7+/+ and P2rx72/2 mice were
subsequently analyzed in vitro. In these experiments, hippocampal
slices were incubated in the presence of agonist and antagonist of
P2rx7 and their effects on BDNF production were examined.
Consistent with the ex vivo results, the basal BDNF level in the
hippocampal slices of P2rx72/2 mice in these experiments was
significantly higher than detected in P2rx7+/+ mice (Fig. 4B, C,
23.9460.49 pg/ml and 18.3260.39 pg/ml in P2rx72/2 and
P2rx7+/+ mice, n = 8/group, P,0.001).
The selective P2rx7 antagonist, Brilliant Blue G (BBG;
100 nM), significantly enhanced the basal level of BDNF in the
presence of the P2X7 receptor (Fig. 4B; 118.2261.59 pg/ml,
656% increase; n = 4, P,0.01). Therefore, the pharmacological
inhibition of P2X7 receptors reproduced the effect of genetic
deletion in P2rx7+/+ mice. Although BBG also increased the
BDNF protein level in the hippocampus of P2rx72/2 mice
(P2rx72/2: 60.3160.31 pg/ml, 272.7% increase; n = 4,
P,0.001), its stimulatory effect was significantly attenuated in
the deficiency of the P2X7 receptor (Fig. 4B).
Next, we evaluated the effect of the P2X receptor agonist 39-O-
(4-benzoyl-benzoyl) adenosine 59-triphosphate (BzATP) on the
hippocampal BDNF protein level. Because previous studies have
shown that P2rx7 agonist–induced responses are amplified in
Mg2+-free medium e.g. [18], in the subsequent experiments, Mg2+
was omitted from the BzATP incubation medium. BzATP
(100 mM) caused a decrease in the basal level of BDNF production
in P2rx7+/+ mice (Fig. 4C; P2rx7+/+: 13.8560.98 pg/ml,
25.73% decrease; n = 8, P,0.05) without significantly affecting
the BDNF level in the P2rx72/2 mice (Fig. 4C). Moreover, the
observed inhibitory effect of BzATP was reversed by BBG (Fig. 4C;
BBG+BzATP: 77.8764.24 pg/ml, n = 4), indicating that this
inhibitory action is due to the activation of P2rx7.
Literature data and the previous experiments suggested that the
activation of P2rx7 by ATP or BzATP elicits Ca2+ influx [18],
which is followed by an increased glutamate release [19,20,21,22].
Therefore, we examined whether the P2rx7-mediated glutamate
release and its action on various glutamate receptors might be
responsible for P2rx7-mediated alterations in BDNF levels. To this
end, the effect of BzATP on the basal BDNF level was examined
in the presence of the Group I (mGluR1,5) mGluR antagonist,
MCPG (200 mM), CNQX (10 mM) the non-NMDA-type gluta-
mate receptor antagonist, TCN-201 (10 mM) the NR1/NR2A
glutamate receptor selective antagonist and the NR2B glutamate
receptor antagonist, RO-256981 (3 mM). Among the antagonists,
the inhibitory effect of BzATP (100 mM) was occluded by CNQX,
TCN-201 and by RO-256981 (Fig. 4D; RO-256981 alone:
15.2060.12 pg/ml, n = 4; BzATP+RO-256981:15.7560.44 pg/
ml, n = 12, P.0.05) indicating the involvement of both NMDA
and non-NMDA-type ionotropic glutamate receptors in this effect.
In contrast, blockade of mGluR1,5 receptors using MCPG did not
antagonize the inhibitory effect of BzATP (Fig. 4D,
BzATP+MCPG: 6.0961.17 pg/ml, 67.34% decrease n = 4,
P,0.01). Moreover, when applied alone, MCPG significantly
diminished the basal level of hippocampal BDNF, suggesting that
the endogenous activation of Group I mGluR contributes to
BDNF production in the hippocampus. The Group I mGluR
agonist, DHPG, caused a profound elevation in the basal level of
BDNF production in P2rx7+/+ mice (Fig. 4D; DHPG:
41.5960.40 pg/ml, n = 4, P,0.01). Interestingly, BzATP signif-
icantly increased BDNF levels in the presence of DHPG (Fig. 4D;
BzATP+DHPG: 54.1461.92 pg/ml, n = 4, P,0.05).
BrdU Incorporation Experiments
In these experiments, we used the proliferation marker BrdU to
evaluate adult neurogenesis and examined the average number of
BrdU-positive cells in the dentate gyrus (DG), which contains the
granular cell layer and its subgranular zone at no more than
50 mm apart. There was a significantly higher average number of
BrdU-positive cells in the DG of the rostral hippocampal sections
of P2rx72/2 mice compared with P2rx7+/+ mice (Fig. 5A, B, C).
Although the difference between the two genotypes was not
robust, we consistently observed, except in one case, more BrdU-
positive cells in the DG of P2rx72/2 mice than in their P2rx7+/+
littermates.
Dysregulation of Biogenic Amine Levels in the
Hippocampus of P2rx72/2 Mice
The 5-HT and NA content was measured using HPLC in the
hippocampus of naı¨ve, untreated and LPS-treated (1 mg/kg i.p.)
P2rx7+/+ and P2rx72/2 mice. A significantly elevated basal
expression of 5-HT was observed in untreated P2rx72/2 mice
(Fig. 6A) compared with P2rx7+/+ mice, whereas the 5HIAA/5-
HT ratio was profoundly decreased in the hippocampus of
P2rx72/2 mice (2.0760.57 and 0.3160.08 in P2rx7+/+ and
P2rx72/2 animals, respectively, n = 14–22, P,0.01). The NA
levels were also significantly decreased in response to genetic
deletion (Fig. 6B).
LPS treatment significantly increased 5-HT levels in the
hippocampus (Fig. 6A) of P2rx7+/+ mice. This elevation was
absent in P2rx72/2 mice; moreover, the 5-HT level was
decreased in response to endotoxin treatment (Fig. 6A). By
contrast, LPS treatment did not affect the NA content in the
hippocampus in either genotype (Fig. 6B).
[3H]5-HT/[3H]NA Release Experiments
As a functional readout of monoaminergic neurotransmission
[3H]5-HT and [3H]NA release experiments were also performed
in acute hippocampal slices.
In [3H]5-HT release experiments, there was no significant
difference in the resting- and electrically-evoked [3H]5-HT efflux
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between P2rx7+/+ and P2rx72/2 mice (Table 1). Likewise,
when tissue slices were loaded with [3H]NA, the resting [3H]NA
release was similar in the hippocampal slices of P2rx7+/+ and
P2rx72/2 mice (Table 1). As a potential correlate of decreased
NA levels in the deficiency of functional P2rx7, the electrical
stimulation evoked [3H]NA efflux in the hippocampus was slightly,
but significantly decreased in P2rx72/2 mice (Table 1).
3H-5HT Uptake and 3H-Citalopram Binding are Enhanced
in the Hippocampus of P2rx7 Knockout Mice
To examine, whether alterations in tissue monoamine levels
results from a change in the uptake, we examined the 5-HT and
NA transporters using the specific ligands, [3H]Citalopram and
[3H]Nisoxetine, and measured the 5-HT uptake in synaptosomal
preparations. As shown in Fig. 6C, the uptake in the synaptosomal
preparation of the P2rx7+/+ mouse hippocampus was
1627647 fmol/mg protein (n = 4) using 561028 M 5-HT,
whereas the uptake slightly but significantly (P,0.04) enhanced
to 1816652 fmol/mg protein (n = 4) in P2rx72/2 mice. The
[3H]Citalopram-labeled 5-HT transporter demonstrated saturable
binding with no significant changes in the Kd value in the
hippocampal membranes of either genotype (Table 2); however, a
significant increase was observed in the Bmax of P2rx72/2 mice
compared with P2rx7+/+ littermates (Fig. 6C, Table 2). To assess,
whether the deletion of P2rx7 affected the NA transporter, the
binding of the specific ligand 3H-Nisoxetine was examined. No
difference was observed in 3H-Nisoxetine binding parameters
between P2rx7+/+ and P2rx72/2 mice in the hippocampus
(Table 2). As b-adrenergic receptors are downregulated after
chronic antidepressant treatment [54], we also studied the binding
of 3H-dihydroalprenolol. There was no difference in the affinity of
the receptors or the number of binding sites in the hippocampal
membranes of the two genotypes (Table 2).
Discussion
Recent studies highlighted that P2X7 receptors play a
regulatory role in a number of CNS-related functions, including
learning and memory [55], sleep [56], fever [57] and behavior
[23,24,25].
In our behavior experiments, we found that P2rx72/2 mice
displayed an antidepressant-like phenotype in two tests, used to
assess mood-related behavioral modifications pertinent to depres-
sion. In the TST model, an increased time of basal immobility was
observed in the deficiency of P2rx7 consistent with the previous
results obtained by our group [25] and of others using similar
behavioral protocols [23,24]. In our previous study, we also
showed that similar changes could be reproduced by the
pharmacological blockade of P2rx7 using the selective and in vivo
active [58] P2rx7 antagonist Brilliant blue G. In the present study,
we extended these data, showing that Brilliant blue G also
counteracts bacterial endotoxin-induced depressive behavior,
which suggests that P2rx7 regulates stress-induced depressive
behavior.
Whereas the increased immobility in TST reflects the deficit in
active coping strategy against negative environmental stimuli,
another important aspect of depression is anhedonia, which is
modeled in animal experiments by a decreased preference for
sucrose in the SPT test. We have precipitated anhedonia in our
experiments by a relatively mild endotoxin challenge, which
elicited a selective decrease in sucrose, but not water consumption.
Following the protocol, described by a previous study [41], the
depression-like behavior can be temporally separated from the
early symptoms of sickness behavior, such as the robust depression
of motor activity and food intake [59]. Nevertheless, it should be
noted that some behavioral, biochemical and electrophysiological
changes persist days after LPS exposure and that even with this
clear distinction LPS induced anhedonia response is only similar
but not identical to depressive behavior characteristic to human
major depression: whereas the former represents an adaptive
response to infection, the latter occurs in the absence of immune
challenge.
In our experiments, a significantly attenuated anhedonia
response was observed in the deficiency of P2rx7, which could
be pharmacologically reproduced using Brilliant blue G and
another potent P2rx7 antagonist, AZ-10606120 [60]. Notably,
AZ-10606120 was active upon acute application and displayed a
higher potency than the potent antidepressant compound
citalopram. Moreover, the effect of AZ-10606120, but not
citalopram, was significantly attenuated in P2rx72/2 mice,
confirming the involvement of P2rx7 in this effect. Interestingly,
both AZ-10606120 and BBG was more effective in this test than
the deletion of P2rx7. The compensatory upregulation of other
P2X receptors, or the C-terminal truncated variant of P2rx7,
which is not inactivated in the Pfizer-type knockouts [61] could be
responsible for the discrepancy. In fact, we have previously showed
the upregulation of P2rx4 in the striatum of the same P2rx7–
deficient mouse line [62]. Another potential explanation is a
P2rx7-independent component in the effect of antagonists. On the
other hand, the relatively weak effect of acute citalopram
treatment is consistent with previous literature data showing that
anhedonia is largely sensitive to subacute or chronic, but not acute
antidepressant treatment [63].
Overall, the behavioral data obtained in this study, together
with previous results [23,24,25], provides further support for the
hypothesis that P2X7 receptors regulate emotional behavior in
animal models of depression.
To identify cellular actions that mediate the action of P2rx7 on
mood-related behavior, we have chosen the hippocampus as the
target area of our present studies. The rationale of the choice of
hippocampus was two-fold: 1) a previous study [24] found that in
parallel with a decreased response to repeated forced swimming
test in P2rx72/2 animals a reduction in c-fos immunoreactivity
was detected in the amygdala and hippocampus. 2) In our
previous study P2rx7-dependent neurochemical alterations have
already explored in the amygdala [25]. We have to note, however,
that P2rx7-dependent changes in hippocampal signaling pathways
found by the present study might also underlie other hippocampal
functions such as memory formation. In fact, it has been described
that there is a spatial memory deficit in the deficiency of P2rx7
[55], which was found to be correlated with impaired interleukin-
1b and c-Fos expression in the hippocampus. On the other hand,
non-hippocampal mechanisms might also participate directly or
indirectly in the action of P2rx7 on mood-related behavior.
We examined glutamatergic transmission because one impor-
tant function of P2rx7 activation in the brain is to promote the
release of glutamate [19,20] and previous observations from
animal and human studies strongly indicate that excessive
glutamatergic transmission might be involved in the pathophys-
iology of depressive disorders [64]. These findings include
abnormalities in glutamate levels, e.g., [65], genetic polymorphism
[66] and the differential expression of NMDA and AMPA
receptor subunits in BPD and MDD patients [67,68]; antidepres-
sant properties of glutamate receptor antagonists and modulators
[69]; and the regulation of glutamate receptor subunits by
clinically used antidepressants [70,71]. Moreover, in our previous
study, consistent with the presumed dysfunction of glutamatergic
transmission and consequent neuroplasticity changes in depression
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[69,72], the downregulation of different AMPA and metabotropic
glutamate receptor subunits and the upregulation of the NR2B
subunit of NMDA receptors was detected in the amygdala of
P2rx72/2 mice [25]. The real–time PCR analysis conducted in
the present study revealed that the upregulation of the NR2B
subunit of NMDA receptors also occurs in the hippocampus,
which is another component of the limbic system. In addition, the
results of the present study demonstrated that ATP elicits
concentration-dependent tritiated and endogenous glutamate
efflux in the hippocampus, and P2X7 receptors mediate the
majority of this glutamate efflux, whereas a minor, residual portion
of the glutamate release detected in the P2rx72/2 mice is
mediated through P2X1 receptors. We also show that the basal
[3H]Glu efflux is lower in the hippocampi of P2rx7 deficient
animals, which is indicative for a lowered basal extracellular
glutamate levels under the conditions of behavior experiments.
These data are consistent with previous results showing that the
activation of P2rx7 in the brain leads to increased glutamate
release from the nerve terminals [19,20,22] and astrocytes [73],
and both P2X7 and P2X1 receptors are expressed in the
hippocampus [74]. Therefore the source of P2rx7 mediated
glutamate release could be either neuronal or glial. Another
possibility is that P2rx7 controls astrocytic glutamate uptake in the
hippocampus; however this assumption needs further investiga-
tion.
A potential pathway, whereby increased glutamate release may
lead to a change in mood is the alteration of the level of
neurotrophic factors. Among them, BDNF is the most widely
distributed neurotrophin in the CNS, and it plays several roles in
synaptic plasticity and neuronal survival [75,76]. The role of
hippocampal BDNF and subsequent neurogenesis in depression
and in the therapeutic action of antidepressants is an emerging
hypothesis, which is supported by many experimental data
[26,77,78,79]. As a consequence, BDNF has become a key target
in the pathology of several neurological and psychiatric diseases
[80], and clinical studies have shown that BDNF protein
expression is significantly decreased in both the serum and brain
of depressed patients [29,81,82]. Therefore, we characterized the
potential changes in BDNF expression in the hippocampus of wild
type and P2rx72/2 mice. In our ex vivo study, we observed
elevated basal BDNF levels in the hippocampus of P2rx72/2
mice compared with the corresponding saline-treated P2rx7+/+
controls. After systemic LPS challenge, we detected a decrease in
BDNF protein expression in both genotypes. These results are
consistent with previous data showing that hippocampal BDNF
expression is significantly decreased at both the mRNA and
protein levels in response to systemic LPS treatment [83,84].
However, our results also imply that whereas an alteration in
BDNF levels might be a mediator of P2rx7-dependent changes in
behavior in the absence of LPS, e.g., the decreased basal
immobility in the TST test (Fig. 1A), P2rx7-mediated glutamate
efflux and subsequent changes in BDNF levels play only a minor
role in the P2rx7-dependent regulation of LPS-induced depressive
behavior (Fig. 1 B, C).
To explore the local regulatory role of P2X7 receptors in the
modulation of basal BDNF production, we conducted an in vitro
study. In support of the ex vivo results, the basal BDNF expression
in the hippocampal slices of P2rx72/2 mice was significantly
higher than in P2rx7+/+ mice, indicating a tonic inhibitory
regulation of BDNF production through P2rx7. This was further
confirmed using BBG, the selective P2rx7 antagonist; although
BBG significantly increased the level of BDNF expression in both
P2rx7+/+ and P2rx72/2 mice, its facilitatory effect was
significantly attenuated in the deficiency of the P2X7 receptor.
Interestingly, similar to our in vivo behavior studies, the pharma-
cological blockade of P2rx7 elicited a more pronounced effect than
the genetic deletion, which could be explained by compensatory
gene expression changes in case of genetic deletion.
When hippocampal P2rx7 was stimulated through the P2X
receptor agonist BzATP, a significant decrease in BDNF protein
expression was detected in P2rx7+/+ mice, which was absent in
P2rx72/2 mice and reversed using BBG. These data indicate
that BDNF levels in the hippocampus are under the local
regulatory influence of P2rx7. To our knowledge, our study is
the first to demonstrate a role for P2rx7 in the regulation of BDNF
production in the central nervous system. In contrast, in the
periphery, P2X7 receptor activation could induce the vesicular
release of BDNF from the Schwann cells, which in turn might play
a trophic role on neurons [85].
Because our previous data indicated that P2rx7 activation
primarily releases glutamate [19,20], we explored the role of
glutamate receptors in the inhibitory action of BzATP on
hippocampal BDNF protein expression. The inhibitory effect of
BzATP was completely reversed by CNQX, the non-NMDA
receptor antagonist TCN-201, the NR1/NR2A selective gluta-
mate receptor antagonist and by the NR2B receptor selective
antagonist RO-256981. These results indicate that the activation
of both non-NMDA and NMDA receptors are necessary
conditions for the P2rx7-mediated inhibitory regulation of BDNF
level. Taken into account that glutamate receptor antagonists by
themselves decreased BDNF production, consistently with the key
role of synaptic glutamate receptor activation in the induction of
BDNF [86,87], a possible interpretation of our results is that
glutamate released by P2rx7 activation primarily acted on
extrasynaptic NMDA receptors, which are able to shut-off the
induction of BDNF [86], but only if synaptic glutamate receptors
are also co-activated. Because among NMDA receptor subunits,
NR2B are primarily localized to extrasynaptic sites in the
hippocampus [88,89,90] we propose that P2X7 receptor activa-
tion leads to increased glutamate release and to subsequent
overactivation of extrasynaptic NR2B receptors. NR2B activation,
in turn, downregulates BDNF expression and thereby causes long-
lasting changes in neuronal plasticity, which might underlie
pathological changes in behavior. The upregulation of hippocam-
pal NR2B subunits after the genetic deletion of P2X7 receptors
observed in these experiments also supports this proposed
mechanism, consistent with the presumed dysfunction of gluta-
matergic transmission [91,92] and consequent changes in
neuroplasticity during depression [69,72].
On the other hand, in the absence of exogenous activation of
P2rx7 by BzATP, BDNF levels were decreased (CNQX, RO-
258981) or unaffected (TCN-201) by ionotropic glutamate
receptor antagonists, which implies that the net effect of
endogenous P2rx7 activation and other signaling pathways
converging on ionotropic glutamate receptors on BDNF level is
stimulatory.
In contrast, effect of BzATP was not alleviated through the
mGluR1,5 selective receptor antagonist, MCPG, whereas the
administration of mGluR1,5 selective agonist DHPG, significantly
increased BDNF expression in the presence and absence of
BzATP. Therefore, mGluR1,5-mediated facilitatory modulation of
hippocampal BDNF expression seems to be independent from the
activation of P2rx7, consistently with the idea that BzATP-
mediated glutamate release preferentially activates extrasynaptic
NMDA receptors. Treatment with MCPG alone resulted in
decreased BDNF expression, whereas DHPG treatment increased
BDNF production, consistent with the well-known stimulatory role
of mGluR1,5 receptors in BDNF production e.g. [93]. Interest-
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ingly, we also observed that BzATP paradoxically increased
BDNF expression in the presence of the mGluR1,5 agonist,
DHPG. This effect, which requires further investigation, is most
likely independent from the activation of P2rx7.
In addition to the regulation of BDNF production, previous
studies have associated neurogenesis with the beneficial actions of
specific antidepressants, suggesting a connection between de-
creased hippocampal neurogenesis and depression [94,95]. Others
have hypothesized that neurogenesis might promote neuroplasti-
city [96,97]. Our study revealed that basal level of neurogenesis
detected using BrdU staining is higher in the deficiency of the
P2X7 receptor in the dentate gyrus, suggesting that the
endogenous activation of P2rx7 inhibits adult neurogenesis in
the hippocampus through the regulation of BDNF levels or
independently from it. Thus we cannot exclude the possibility that
P2rx7 directly regulates hippocampal neuronal survival/neuro-
genesis without the involvement of glutamate or neurotrophic
factors. Consistent with this latter assumption, the results of
electrophysiological studies have shown that neuronal progenitor
cells (NPCs) from the adult rat hippocampus [98,99] and
embryonic mouse striatum [100] express functional P2rx7.
Activation of P2rx7 elicits necrotic cell death in the latter [100]
and the inhibition of P2X7 receptors promotes axonal growth in
cultured hippocampal neurons [101]. Therefore, further in situ
analysis on the effect of the genetic deletion and pharmacological
antagonism of P2rx7 on NPC survival and neurogenesis is of
potential interest.
Taken together, the results obtained in this study provide
several possible mechanisms to explain the antidepressant
phenotype observed in the deficiency of P2rx7 [23,24]. However,
the signaling pathways mediating the effect of P2rx7 activation on
stress-induced depressive behavior, i.e., those evoked through
bacterial endotoxins, remains to be established. Thus, we
determined whether neurochemical markers of monoaminergic
transmission are changed in the hippocampus after genetic
deletion of P2rx7 in saline and LPS-treated animals. Under basal
conditions, we detected a dysregulation of monoaminergic
transmission, and these results are consistent with our previous
findings in the amygdala [25]. We observed elevated 5-HT levels
and a decreased 5HIAA/5-HT ratio, reflecting the increased
bioavailability of 5-HT, together with decreased basal NA levels.
As an explanation for the elevated 5-HT levels, the number of
[3H]Citalopram binding sites and the [3H]5-HT uptake was
significantly higher in the hippocampus in the deficiency of P2rx7,
whilst there was no difference in basal and stimulation-evoked
[3H]5-HT release in the two genotypes. These findings are
reminiscent of the effects of chronic antidepressant treatment,
which increases the uptake of 5-HT in hippocampal slices [102].
However, we did not observe any change in NA transporter
binding sites, and the ß-receptors were not downregulated,
although it was previously published that treatment of rats with
antidepressants reduced the number of ß-receptors, while seroto-
nergic terminals remained intact [54]. The question arises whether
the detected changes in serotonergic signaling in the hippocampus
P2rx7 deficient mice are the cause or consequences of the
alteration in glutamate and BDNF levels and neurogenesis, or
parallel changes. The relationship between hippocampal seroto-
nergic transmission, BDNF, neurogenesis and depressive behavior
has been explored in numerous studies and there are several links
between them. BDNF is critical for the normal development and
function of central 5-HT neurons and the elaboration of behaviors
that depend on the activity of these neurons [103,104,105]. As an
example, elevation of extracellular 5-HT and antidepressant-like
behavioral effects in the FST test by SSRI antidepressants are
completely eliminated in mice deficient in BDNF (BDNF+/2)
[104,105] and a decrease in the [3H]5-HT uptake and
[3H]citalopram binding densities are found in these mice [106],
the opposite that is detected in P2rx7 deficient mice.
Interestingly, LPS treatment caused a significant elevation in 5-
HT expression in the hippocampus of P2rx7+/+ mice, which was
completely absent in P2rx72/2 mice; moreover, the 5-HT levels
were depleted in these mice. Therefore, the direct or indirect
modulation of serotonergic transmission is a potential mechanism
that might underlie the action of P2rx7 to regulate stress-induced
changes in mood-related behavior, although the possibility that
alterations in 5-HT levels occur as a compensatory change in
response to changes in behavior cannot be excluded.
Finally, it should be noted that although the present study
focused on P2rx7, this is not the only pathway, whereby
endogenous ATP or other purines could affect depressive
behavior. ATP is a ubiquitous signaling molecule and the majority
of its ionotropic (P2X1-7) and metabotropic (P2Y1,2,4,6,11,12,13,14)
receptors are also expressed in the hippocampus and other brain
regions involved in the processing of depressive behavior. The
identification of the role of these receptors, however, awaits further
investigation.
In conclusion, our data show that the genetic deletion of P2rx7
leads to an antidepressant phenotype associated with changes in
hippocampal monoaminergic transmission, neurotrophin protein
expression and adult neurogenesis in the dentate gyrus. Moreover,
these data support the view that P2rx7 antagonists might have
therapeutic potential in mood-related disorders.
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